Anthem Biosciences Ltd

Anthem Biosciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 April 2026. While the rating change occurred on that date, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 24 April 2026.

Anthem Biosciences Ltd has seen its investment rating upgraded from Sell to Hold as of 10 April 2026, reflecting a notable improvement in technical indicators alongside steady fundamental performance despite recent quarterly setbacks. The mid-cap pharmaceutical and biotechnology company’s Mojo Score has risen to 50.0, signalling a more balanced outlook for investors amid mixed financial trends and valuation concerns.

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable shift in price momentum and technical indicators, signalling a cautiously optimistic outlook after a period of subdued performance. The stock’s recent 4.76% intraday gain to ₹722.70, coupled with upgrades in key technical parameters, suggests a mild bullish trend emerging in the near term.

The Sensex declined by 0.68% on 09 Apr 2026, while Anthem Biosciences Ltd surged 5.83%, outperforming its Pharmaceuticals & Biotechnology sector by nearly 5 percentage points. This strong single-session gain stands out as a stock-specific event amid a broadly weak market backdrop.

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish to a mildly bearish trend. Despite a 3.39% gain on 9 Apr 2026, the stock’s technical indicators present a complex picture, signalling caution for investors amid mixed signals from MACD, RSI, and moving averages.

Anthem Biosciences Ltd has shifted from a sideways technical trend to a mildly bullish stance, supported by key momentum indicators such as the MACD and Bollinger Bands. Despite a modest day change of 0.43%, the stock’s technical parameters suggest a cautiously optimistic outlook amid a challenging broader market environment.

Anthem Biosciences Ltd has seen its investment rating downgraded from Hold to Sell as of 6 April 2026, reflecting a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns. The mid-cap pharmaceutical and biotechnology firm’s Mojo Score has declined to 40.0, signalling caution for investors amid sideways technical trends and weakening profitability metrics.

Anthem Biosciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a period of consolidation in the Pharmaceuticals & Biotechnology sector. Despite a modest decline in the daily price, the stock’s technical indicators reveal a nuanced picture that investors should carefully analyse amid broader market conditions.

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 1 April 2026. This change reflects a nuanced reassessment of the company’s quality, valuation, financial trends, and technical outlook amid mixed quarterly results and evolving market conditions.

Anthem Biosciences Ltd is rated Sell by MarketsMOJO. This rating was last updated on 09 Mar 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 01 April 2026, providing investors with the latest perspective on the company’s position.

While the Sensex tumbled 2.26% on 27 Mar 2026, Anthem Biosciences Ltd defied the broader market weakness with a robust 6.45% gain, reaching an intraday high of Rs 681. This 5.5 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Anthem Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Anthem Biosciences Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest day gain of 1.82%, the stock’s technical indicators present a complex picture, reflecting mixed signals across weekly and monthly timeframes. This analysis delves into the recent price action, key technical indicators such as MACD, RSI, moving averages, and broader market comparisons to provide investors with a comprehensive view of the stock’s current positioning.

Anthem Biosciences Ltd has seen its investment rating downgraded from Hold to Sell as of 9 March 2026, reflecting a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns. The company’s Mojo Score has declined to 40.0, signalling caution for investors amid sideways technical trends and weakening profitability metrics.

Anthem Biosciences Ltd experienced a notable decline today, touching an intraday low of Rs 608.4, reflecting sustained price pressure amid broader market weakness and sector underperformance.

Anthem Biosciences Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish stance to a sideways trend. Despite a recent downgrade in its Mojo Grade from Sell to Hold, the stock’s technical indicators reveal a complex picture of mixed signals, reflecting cautious investor sentiment amid volatile price action.